Led by $1bn acquisition of MediFox DAN Group, Europe’s medical devices industry saw a rise of 8.57% in cross border deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 76 cross border deals worth $3.5bn were announced for the region during Q2 2022, against the last four-quarter average of 70.00 deals.

Of all the deal types, M&A saw most activity in Q2 2022 with 36 deals, representing a 47.4% share for the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In second place was venture financing with 31 deals, followed by private equity deals with nine transactions, respectively capturing a 40.8% and 11.8% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $2.16bn, while private equity and venture financing deals totalled $874.2m and $464.06m, respectively.

Europe medical devices industry cross border deals in Q2 2022: Top deals

The top five medical devices cross border deals accounted for a 74.9% share of the overall value during Q2 2022.

The combined value of the top five cross border deals stood at $2.62bn, against the overall value of $3.5bn recorded for the quarter.

1) ResMed $1bn acquisition deal with MediFox DAN Group

2) The $797.86m private equity of SPT Labtech by EQT IX Fund

3) Wallaby Medical $541.63m acquisition deal with Phenox

4) The $141.73m acquisition of Aran Biomedical by Integer

5) Straumann $138.06m acquisition deal with SunshineSmile